LifeMD: third-quarter revenue misses guidance while EBITDA nears breakeven
LifeMD reported third-quarter revenue below guidance and cut its 2026 outlook. According to TradingView, adjusted EBITDA improved to near breakeven.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, LifeMD's third-quarter revenue came in below the company's guidance. The shortfall came from delayed fulfillment of branded GLP-1 orders and lower marketing spending. Adjusted EBITDA, however, improved to near breakeven.
The company lowered its 2026 guidance. Its growth plans for 2027 depend on pharmacy operations, enterprise distribution and stronger unit economics, the source summary says.
why it matters
For investors, the key question is whether revenue can recover without renewed marketing spending. The report shows cost discipline, but weak sales remain the main risk.
tags
instruments
sources
- LFMD: Branded GLP-1 fulfillment and tighter costs underpin growth after a Q3 revenue miss — TradingView, 12 November 2026 at 22:55 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗